A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)
about
Approaches to preventative and therapeutic HIV vaccinesVaccine applications of flow cytometryProfiling immunity to HIV vaccines with systems biologyA global approach to HIV-1 vaccine developmentNew concepts in HIV-1 vaccine developmentEfficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules.Systems serology for evaluation of HIV vaccine trials.Molecular mechanisms for enhanced DNA vaccine immunogenicity.Modeling HIV vaccine trials of the future.Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.The duration of antigen-stimulation significantly alters the diversity of multifunctional CD4 T cells measured by intracellular cytokine stainingHIV-1 vaccines: challenges and new perspectivesNovel directions in HIV-1 vaccines revealed from clinical trialsSafety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesDissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters.Protective effect of a prime-boost strategy with the Ts87 vaccine against Trichinella spiralis infection in miceRecombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyHomologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trialTherapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC)Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialA Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.Human immunodeficiency virus vaccinesHIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.In vitro sensitization of T cells with DC-associated/delivered HIV constructs can induce a polyfunctional CTL response, memory T-cell response, and virus suppressionEffect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsContinued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.Use of placebos in Phase 1 preventive HIV vaccine clinical trialsHIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.New prospects for a preventive HIV-1 vaccine.Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsThe future of human DNA vaccinesRelevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)
P2860
Q26764851-41641D79-1922-44A8-9977-7833A33FCCA1Q27004341-2A24B93B-E9C2-4D68-9C8E-50E016A81F7CQ27010629-E2270597-E65D-4E68-A70A-29C872CE15C5Q27024614-E91CB83E-0552-4159-A65B-672C725A94A0Q28067027-279D8D0A-47BB-426E-B6EC-D8CA355C80D5Q30204348-56986C19-E551-416B-9E1D-4CC688A4999DQ30238729-8F086B6D-7716-4558-8A23-8DE1B3063516Q30366743-3F5ABC06-D421-46D6-B2B9-31856001DF92Q30393307-CAB3A0FC-7793-4D1C-B32E-07AA05246124Q30578618-D900EEFF-7C7E-4F62-A0BC-F6904B4AC79DQ30620607-7F32A2EA-E1FC-406A-9746-B4C5B23815D8Q31068532-60CCC8DC-FAE7-4EBC-AB32-8435580EE2B0Q33577972-3C4F2616-9445-4AB1-9F06-5A02E812E360Q33645528-E6E7DBFF-0471-4544-A4F9-502A48CEC16DQ33737476-1C9B6C9E-175A-461B-B432-315E3D6913C9Q33813145-D0C06BA3-24AD-4A84-B37A-12BF7799578FQ33851717-23779F29-C632-41F1-B869-8D082CD8B0ABQ34140468-A6E1F930-1877-48B4-9393-1E291FD22A1AQ34183489-E1C111AA-8B8E-417B-9793-47930674A1F8Q34240204-F8E5FCE1-BB60-42C0-A53A-B4B2E7E90B54Q34263835-6434F2C0-416D-4F9D-B865-4298BF1ABC7FQ34663554-C076DAF9-C062-40F9-8205-A6E2A9F4636FQ35060232-86A1AEA5-DC11-48B5-AF81-DF13EF74A55AQ35118834-8FC4807A-9D85-4F96-AEB0-2419422D3FA2Q35140001-5A3B8723-754A-44E4-9A4B-8B992BFDC74CQ35593139-0CD3613F-E566-43F7-933B-19ACD3694855Q35611969-702B72D5-8359-4B0A-8EFE-B02EC66C3AC5Q35674731-C350783C-FEFA-462F-9BFF-F21895D75B32Q35677513-ABF1BC00-54C2-400E-9239-1BF47BE5C5DCQ35728947-7764FB4A-1D9B-4A60-A3CC-FF3BC13212FCQ35731441-0EB4AD2D-859F-4EDD-8776-03479EE74DE7Q35762443-A3F8ABC3-4B45-4429-B670-39BFCC471EAEQ35774494-61D129F6-E855-4699-B033-FF59FE7D95FFQ36011214-96CCBB8D-9D60-4502-8B58-C9DB566D25A3Q36097352-66D590BE-E952-4025-B065-6A2F560701F7Q36223864-197908FC-F57E-4B58-B4C7-A92F3B64BCC0Q36288468-5AEE8844-4488-4177-A886-81959327267FQ36438236-E3412345-141B-48A7-8C59-E029DC3250BDQ36474557-48754C0C-FB51-4B4A-99CC-A97EF141BA46Q36495581-A51B674D-0D53-46E1-BA43-245E363056C7
P2860
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@ast
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@en
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@nl
type
label
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@ast
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@en
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@nl
prefLabel
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@ast
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@en
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@nl
P2093
P2860
P50
P3181
P1433
P1476
A phase IIA randomized clinica ...... st in healthy adults (HVTN204)
@en
P2093
Artur Kalichman
Cecilia Morgan
Doug Grove
Elizabeth Adams
Georgia D Tomaras
J Peter Figueroa
John Hural
Michael C Keefer
Olivier Defawe
Paul Goepfert
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0021225
P407
P50
P577
2011-01-01T00:00:00Z